Corestemchemon Inc 166480
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ₩12,590.00
- Day Range
- ₩12,460.00–14,420.00
- 52-Week Range
- —–—
- Bid/Ask
- ₩13,890.00 / ₩13,900.00
- Market Cap
- ₩346.33 Bil
- Volume/Avg
- 993,265 / 155,132
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.63
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- < 0.01%
Company Profile
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 371
- Website
- http://www.corestemchemon.com
Comparables
Valuation
|
Metric
|
166480
|
005690
|
4592
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 184.51 | — |
Price/Book Value | 17.66 | 3.81 | 51.78 |
Price/Sales | 11.63 | 5.76 | — |
Price/Cash Flow | — | 43.95 | — |
Price/Earnings
166480
005690
4592
Financial Strength
|
Metric
|
166480
|
005690
|
4592
|
|---|---|---|---|
Quick Ratio | 0.29 | 4.51 | 4.75 |
Current Ratio | 0.31 | 9.82 | 5.30 |
Interest Coverage | −7.66 | — | −202.54 |
Quick Ratio
166480
005690
4592
Profitability
|
Metric
|
166480
|
005690
|
4592
|
|---|---|---|---|
Return on Assets (Normalized) | −32.27% | 2.56% | −46.86% |
Return on Equity (Normalized) | −124.84% | 3.10% | −95.71% |
Return on Invested Capital (Normalized) | −45.86% | 2.87% | −73.10% |
Return on Assets
166480
005690
4592
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Lpkjbbvyj | Hdwc | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ygzzlxcxg | Blgfby | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mqylwrd | Hsvwpm | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rqdkttpwp | Xgpzfx | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Jrvrzvxd | Xcqqy | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Nhbjgjny | Nhspm | $29.2 Bil | |||
| Moderna Inc
MRNA
| Wqblqtdc | Lzmt | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Tyswgbmj | Nslxg | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dsqdqvp | Rlmlq | $13.2 Bil | |||
| Incyte Corp
INCY
| Tllnsscf | Ykgkmwm | $13.0 Bil |
United States